Eir Ventures co-leads high profile syndicate in €55 million investment in Galecto Biotech.
The company is based on science and technology stemming from Swedish academia and developed in Denmark. The technology addresses fibrotic diseases with limited or no care available today.
The investment is a result of Eir Ventures’ capacity to evaluate, structure and lead investments of this size, and of our deep understanding and knowledge of the company‘s potential as two of Eir Ventures Partners’ founders, Magnus Persson and Stephan Christgau, until recently served as Chairman and Director of the board, respectively.
Eir Ventures will appoint Stephan Christgau to the Galecto board.